Stock Price & Volume | Full Chart
Ipsen extends expiration date of tender offer for Albireo Pharma, Inc. to 1 March 2023
Globe Newswire (Wed, 22-Feb 1:00 AM ET)
FDA Grants June 15, 2023 PDUFA Date to Albireo for Bylvay in Alagille Syndrome
Globe Newswire (Tue, 14-Feb 8:30 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TIG, ALBO, LPTX
ACCESSWIRE (Thu, 9-Feb 7:50 AM ET)
Moore Kuehn Encourages ALBO, LPTX, ALR, and CEMI Investors to Contact Law Firm
Globe Newswire (Wed, 8-Feb 12:27 PM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OSH, AJRD, ALBO, ALR
ACCESSWIRE (Wed, 8-Feb 8:30 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TIG, ALBO, PAYA
PRNewswire (Tue, 7-Feb 1:18 PM ET)
SHAREHOLDER ALERT: Weiss Law Reminds AQUA, LPTX, CNCE, and ALBO Shareholders About Its Ongoing Investigations
PRNewswire (Mon, 6-Feb 4:53 PM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALBO, AJRD, CBIO, STAR
Globe Newswire (Fri, 3-Feb 7:27 AM ET)
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALBO, PAYA, CEMI
ACCESSWIRE (Thu, 2-Feb 6:45 AM ET)
ALBO STOCK ALERT: HALPER SADEH LLC IS INVESTIGATING WHETHER THE SALE OF ALBIREO PHARMA, INC. IS FAIR TO SHAREHOLDERS
ACCESSWIRE (Wed, 1-Feb 6:15 AM ET)
Albireo Pharma Inc is a commercial-stage biopharmaceutical company. It focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. The Company's product pipeline includes Bylvay, which is approved in the United States and Europe; elobixibat, which is approved in Japan for the treatment of chronic constipation; A3907, its Phase 1 lead candidate for the treatment of adult liver diseases; and A2342, it's a lead preclinical candidate for the treatment of adult viral and liver diseases.
Albireo Pharma trades on the NASDAQ stock market under the symbol ALBO.
As of March 22, 2023, ALBO stock price was flat at $44.15 with million shares trading.
ALBO has a beta of 0.55, meaning it tends to be less sensitive to market movements. ALBO has a correlation of 0.02 to the broad based SPY ETF.
ALBO has a market cap of $915.89 million. This is considered a Small Cap stock.
Last quarter Albireo Pharma reported $10 million in Revenue and -$1.92 earnings per share. This beat revenue expectation by $292,000 and missed earnings estimates by -$.86.
In the last 3 years, ALBO stock traded as high as $49.00 and as low as $14.37.
The top ETF exchange traded funds that ALBO belongs to (by Net Assets): VTI, VXF, NTKI.
ALBO has outperformed the market in the last year with a price return of +43.3% while the SPY ETF lost -11.3%. ALBO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +121.1% and 0.0%, respectively, while the SPY returned +3.4% and -1.3%, respectively.
ALBO support price is $43.90 and resistance is $44.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ALBO stock will trade within this expected range on the day.